Giant Cell Tumor of Bone Clinical Trial
Official title:
Clinical, Pathologic Characteristics and Its Mechansim of Denosumab Treated Giant Cell Tumor of Bone
Giant cell tumor of bone (GCTb) is a primary, osteolytic, benign tumor of the bone. Surgery is the commonly used treatment. Discovery of RANKL and its human monoclonal antibody, denosumab, led to use of denosumab for treatment of GCT. The aim of this study was to evaluate clinical and pathological results of treatment of relapsed or refractoriness GCT with denosumab and to assess adverse effect profile and recurrence rate.
Giant cell tumor of bone (GCTb) is an aggressive, benign bone tumor. GCTb, which was first defined by Cooper and Travers, can produce pulmonary metastasis, albeit rarely (1-6%). GCTb constitutes 5% of primary bone tumors and 20% of benign bone tumors. Histologically, the tumour consists of a proliferation of mononuclear cells, accompanied by a population of non-neoplastic osteoclast-like giant cells and mononuclear osteoclast precursors. Currently, it is thought that proliferating neoplastic cells produce a number of cytokines and mediators, including the receptor activator of nuclear factor κ-B-ligand (RANK-RANKL) system, that recruit osteoclast precursors and induce their maturation into multinucleated osteoclast. The standard management of GCTb is based on surgery with several local adjuvant treatments like methacrylate cement, phenol or cryotherapy to reduce the risk of recurrence, while bisphosphonates are used in some cases to decrease bone resorption and for pain relief in inoperable tumours or metastatic disease. In the last 5 years the use of denosumab, a fully human monoclonal antibody already licensed for postmenopausal osteoporosis and prevention of skeletal related events in bone metastases from solid tumours, has been introduced in the treatment strategy of GCTb. In this study we examined the clinical, radiological, histological and underlying mechanism features of a series of GCTb, before and after denosumab administration, comparing baseline and resection specimens. Moreover, we examined the safety of the drug and on the angiogenesis through the determination of microvascular density (MVD). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
| Active, not recruiting |
NCT04255576 -
Efficacy and Safety of JMT103 in Patients With Giant Cell Tumor of Bone
|
Phase 1/Phase 2 | |
| Completed |
NCT03301857 -
Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004
|
Phase 4 | |
| Completed |
NCT05402865 -
A Real-world Study on Patients of Unresectable Giant Cell Tumor of Bone
|
||
| Recruiting |
NCT03295981 -
Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone
|
Phase 3 | |
| Completed |
NCT00464620 -
Trial of Dasatinib in Advanced Sarcomas
|
Phase 2 | |
| Recruiting |
NCT05595603 -
Zoledronic Acid-loaded Bone Cement as a Local Adjuvant Therapy for Giant Cell Bone Tumor After Intralesional Curettage
|
Phase 2 | |
| Not yet recruiting |
NCT03358212 -
Safety and Efficacy of Post-operative Denosumab Strategy for Giant Cell Tumor of Bone Treatment in China
|
N/A | |
| Completed |
NCT04002817 -
Giant Cell Tumor of the Bone in Young Patients
|
||
| Completed |
NCT00396279 -
Safety and Efficacy Study of Denosumab in Patients With Recurrent or Unresectable Giant Cell Tumor of Bone
|
Phase 2 | |
| Terminated |
NCT00889590 -
Adjuvant Zoledronic Acid in High Risk Giant Cell Tumour of Bone (GCT)
|
Phase 2 | |
| Recruiting |
NCT04586660 -
Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone
|
Phase 4 | |
| Active, not recruiting |
NCT03449108 -
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
|
Phase 2 | |
| Not yet recruiting |
NCT05813665 -
A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of Bone
|
Phase 3 | |
| Completed |
NCT02996734 -
Giant Cell Tumor of the Extremities Treated With Surgery and/or Medical Treatment
|
N/A |